Former Lacoste, Under Armor, Nautica Executive to Co-Lead Company’s Textile Sales; Brings 20+ Years of Global Textile Supply Chain Operations, Stewardship and Industry Thought Leadership to Applied DNA

STONY BROOK N.Y., October 4, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, today announced that it has appointed Wayne Buchen as Vice President of Strategic Sales, effective immediately, to lead the Company’s global textile Strategic Sales efforts. With over 20 years of sales, sourcing and operations experience with established international brands, Mr. Buchen will drive the development and execution of sales strategies to expand Applied DNA’s presence across global textile markets.

Mr. Buchen most recently served as Senior Vice President of Global Sourcing and Operations for Lacoste in Hong Kong and Senior Vice President of Global Sourcing in New York. He previously held leadership positions at Under Armor, Li & Fung, VF Corporation, Nautica and Liz Claiborne.

“Wayne’s deep experience with the needs of today’s brands makes him a great and timely fit for Applied DNA as we move to expand our penetration of the global textile market,” said Dr. James A. Hayward, president and CEO of Applied DNA. “His many years of supply chain operations and sourcing for leading apparel brands give him a unique perspective on how to position our CertainT platform for maximum effect for adoption by brands and textile manufacturers worldwide, as business imperatives centered on sustainability and the circular economy continue to be embraced by textile ecosystem participants.”

Mr. Buchen, together with MeiLin Wan, vice president of Textile Sales, will lead the Company’s sales efforts in its textile vertical. Mr. Buchen will be responsible for the strategic sales direction, focusing on business development, key accounts, integrated value chain propositions and new customer relationships and partner development. He will also design and implement go-to-market strategies for new applications of Applied DNA’s CertainT platform in textiles.

Mr. Steve Birkhold, CEO of UL Brands and a veteran of brand creation said: “Wayne has consistently worked on innovative solutions to problem solve many issues throughout his career. This initiative has the opportunity to transform the fashion/textile industry. Wayne’s partnership will add tremendous value to the company.”

“Applied DNA is at a pivotal point where potential partners recognize that our molecular business solutions are critical components of the value chain. The applications for our advanced technology are diverse and I am energized to have Wayne enhancing and expanding our partnerships across the textiles industry,” said Ms. Wan.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT^®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™ and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Applied DNA also leverages its DNA knowledge to the benefit of the biotherapeutics market through, a wholly owned subsidiary that seeks to commercialize the biotherapeutic value of the Company’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Media contact: Angie Mathews, 781-639-4924, angie@cgprpublicrelations.com
Program contact: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com

by Videojet Technologies Inc.

Videojet Technologies and Applied DNA enter strategic partnership to offer new security print platform to diverse commercial ecosystems.

Applied DNA and Videojet have collaborated in the design of co-branded Applied DNA SigNature molecular-tagged Videojet inks, and a co-branded printer that electronically restricts the use of ink cartridges to only those that contain SigNature DNA inks. The relationship brings the potential to empower the tagging of countless commercial items, all of which are candidates for a CertainT licensing agreement, enabling traceability along the entire supply chain. These solutions were jointly introduced last week at Pack Expo 2017 in Las Vegas.

Integrating the technologies from both companies creates a solution that will be offered to the many industries in which both companies are already engaged. The 345,000-install base of Videojet printers code and mark well over 10 billion products each day.

LineaRx Secures New RNA Therapeutics Customers for Contract Research Services
LineaRx offers simplified manufacturing path to RNA Biotherapeutics via linear DNA

STONY BROOK N.Y., October 1, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” ” or the “Company”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has secured multiple new developers of RNA therapeutics as customers for its Contract Research Organization (CRO) services,  utilizing large scale production of linear DNA by Polymerase Chain Reaction (PCR). LineaRx provides these clients a faster, safer and less expensive manufacturing approach for these important biotherapeutics as compared to traditional production methods.

As part of its recent formation, LineaRx subsumed the activities of Applied DNA as a CRO and Contract Manufacturing Organization (CMO) to the biotherapeutics market. LineaRx offers prospective customers and development partners with access to a unique portfolio of patented and proprietary linear DNA technologies designed to effectively optimize delivery, improve targeting, and extend expression of cellular and gene therapy products.

“With its extensive experience in the manufacture of nucleic acids, LineaRx is the ideal partner to support growing demand for research activities.  We are witnessing a rising number of requests from prospective customers as the industry becomes increasingly cognizant of the Company’s value-adding technology that can improve DNA or RNA therapeutics,” stated Dr. James Hayward, president and CEO of Applied DNA. “Over the next 3 months, LineaRx will provide GLP grade, custom DNA, to a number of customers developing RNA vaccines.  We are confident that the results will show LineaRx PCR-produced DNA is well suited for use in the production of RNA therapeutics”.

The RNA-based therapeutic market is rapidly expanding, and is expected to reach $1.2 billion, globally, by year 2020.[1] RNA biotherapeutics include both therapeutics and vaccines and are a relatively new class of drug. When used as a therapeutic, RNA can be utilized for protein production (mRNA based-therapeutics) or in an interfering capacity to inhibit gene expression (antisense/interfering RNA-based therapeutics). This duality of functionality of RNA allows RNA-based therapeutics to target a wide range of indications including cancer, AIDS, rare genetic disorders, neurodegenerative disorders and cardiovascular conditions.

RNA therapeutics are typically manufactured from a DNA template.  When done at scale, the DNAs have historically been obtained from the circular, plasmid DNA grown in bacteria. The circular DNA must be precisely nicked to become linear and must be purified to remove all bacterial toxins and bacterial DNA. In contrast, large-scale, PCR-produced linear DNA is now available as a CRO service from LineaRx. PCR methods are used by RNA developers during bench-scale development, so that RNA drug developers are imminently familiar with this form of DNA and are gratified by its availability in large scale from LineaRx.

“Bacteria used to produce the plasmids contain toxins and pyrogens, that can cause illness and fevers if present in the final therapeutic that is delivered to a patient,” commented Dr. Mike Hogan, VP of Life Sciences for Applied DNA. ”The strengths of LineaRx’s PCR products lie not only in our ability to produce them at scale, but also through their purity in containing only the DNA necessary for the targeted therapeutic function.”

[1] https://www.alliedmarketresearch.com/press-release/RNA-therapeutics-market-is-expected-to-reach-1-billion-globally-by-2020.html

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

In all forms of gene therapy, DNA exerts its influence from within the nucleus.  Recombinant events for circular DNA are permanent and alter the genomes of the affected cells and their progeny. The fundamental challenge of all gene and cellular therapies is safety.  Recent studies have elaborated “unintended consequences” when plasmid and viral vectors are combined that may pose future risks for treated patients.

When linear DNA enters the nucleus, it does not need to be incorporated into the genome to be temporarily expressed as the intended protein product. LineaRx posits that for the effectiveness of genetic vaccines or genetic immune therapies, transient expression may be sufficient.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT^®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™ and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
program contact: Brian Viscount, Executive Director Product Management, 631-240-8800, brian.viscount@adnas.com

The bigger the better: Applied DNA Sciences and TheraCann International are expanding the scope of their legalized marijuana tagging program.

By GREGORY ZELLER //

Supply-chain security and product-authentication specialist Applied DNA Sciences and Canadian pharmaceutical-solutions provider TheraCann International Benchmark Corp. this week announced an upgraded system designed to accommodate different sizes and type of growers – particularly larger-volume cannabis and hemp growers.

STONY BROOK N.Y., September 25, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that it is launching an additional system to tag the industry’s larger volume cannabis or hemp grows as part of TheraCann International’s ETCH Biotrace™ solution. On the heels of its successful showing of its first Cannabis Tagging System (CTS) in July in San Jose at the NCIA Show, Applied DNA is expanding its cannabis tagging offerings to accommodate different sizes and type of growers in the industry.  The Company’s laboratory services and in-field testing systems round out the solution to support claims of traceability, quality and intellectual properties surrounding a cannabis brand.

“The tremendous interest that came following the show has really accelerated our expansion of tagging solutions to meet the varied cannabis market conditions, including size of grower, indoor, outdoor or hybrid grow, or even the size of plant(s) that justifies the expansion of our tagging equipment solutions,” said Gordon Hope, Director of Cannabis Business Development at Applied DNA Sciences.

The Company’s new design will scale in increments for larger grow operations, enabling these growers an efficient way to tag their cannabis or hemp. The scalable concept utilizes a grow facility’s dry or staging room(s) which can easily be fitted with moveable and expandable POD tagging systems depending upon the size of the room.  The cannabis or hemp present in the room for staging or drying can quickly be tagged without slowing down operations during harvest.

Jason Warnock, CEO of TheraCann International stated, “The expanded portfolio supports and enhances the ETCH Biotrace brand and strategy to offer a comprehensive end-to-end solution to tag, test and track from source to retail shelf.”

ETCH Biotrace combines molecular tagging with TheraCann’s portfolio of licensing, project management, security, cultivation and analysis services.

The Company plans to showcase both the existing CTS design as well as the new POD configuration solution at the upcoming MJBIZCon conference in Las Vegas during the week of November 12, 2018.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-molecular based “CertainT^®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™ and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Sanjay M. Hurry: LHA Investor Relations212-838-3777, shurry@lhai.com
Gordon Hope: Director, Cannabis Markets631-240-8850, gordon.hope@adnas.com
Cheryl Schneider: DGI Comm212-825-3210, cschneider@dgicomm.com

The incidences of counterfeiting continue to escalate–rising from $1.2 trillion in 2017 to an anticipated $1.82 trillion by 2020. Years of technological advancement have made it harder to spot inauthentic products. As a result, consumers are increasingly deceived into purchasing inferior or inauthentic goods. Such products may have been produced using substandard components or in an unregulated factory. The outcome can range from poor product performance to serious safety issues.

Applied DNA Sciences announced yesterday that LineaRx, its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement  with Takis and Evvivax, biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

LineaRx, a subsidiary of molecular technology company Applied DNA Sciences, has entered into a joint development agreement with Italian biotech Takis over developing DNA-based anti-cancer vaccines for humans.

The agreement also includes an alliance with Evvivax, a Takis company, related to the discovery and development of similar vaccines for the veterinary market.

To decrease the threat of counterfeit products in different industries, Applied DNA Sciences has introduced a biochemistry-based innovation in apparel authentication. By partnering with North Carolina–based thread manufacturer American & Efird LLC ( A&E), Applied DNA Sciences unveiled a DNA-tagged thread that includes a DNA marker, which can test authenticity by adding a small amount of activator fluid to a swab that has been brushed on the product to collect a sample.

“Up until now, people used RFID [radio frequency identification], which is a very typical technology, but it’s not specific to the brand,” said MeiLin Wan, Applied DNA Sciences’ vice president of textile sales. “You can’t use the RFID to go to court. DNA has the real big benefit of being considered in court as forensic evidence.”